Last update 04 Nov 2024

Pirtobrutinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
吡托布鲁替尼, LOXO-305, LY 3527727
+ [4]
Target
Mechanism
BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (KR), Priority Review (US), Accelerated Approval (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC22H21F4N5O3
InChIKeyFWZAWAUZXYCBKZ-NSHDSACASA-N
CAS Registry2101700-15-4

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mantle-Cell Lymphoma
KR
19 Aug 2024
Chronic Lymphocytic Leukemia
US
01 Dec 2023
Small Lymphocytic Lymphoma
US
01 Dec 2023
Mantle cell lymphoma recurrent
US
27 Jan 2023
Mantle cell lymphoma refractory
US
27 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapsePhase 2
US
01 May 2024
Multiple sclerosis relapsePhase 2
PR
01 May 2024
Chronic leukemiaPhase 2
CN
14 May 2021
Diffuse Large B-Cell LymphomaPhase 2
CN
14 May 2021
Hodgkin's LymphomaPhase 2
CN
14 May 2021
Hodgkin's LymphomaPhase 2
CN
14 May 2021
Marginal Zone B-Cell LymphomaPhase 2
JP
16 Nov 2018
Marginal Zone B-Cell LymphomaPhase 2
AU
16 Nov 2018
Marginal Zone B-Cell LymphomaPhase 2
FR
16 Nov 2018
Marginal Zone B-Cell LymphomaPhase 2
IT
16 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
25
pmmajibsoi(bdqfwvxtoy) = None gqrgrhxvrq (oxzftepqwt )
Positive
26 Sep 2024
Phase 1
-
32
nsmdfadkfm(ntmwyccasy) = jwpvezslfo sisfierngr (cqggumhhdf, goauwwxbsn - emrkbqwkqc)
-
19 Sep 2024
Phase 2
87
(PAS - MCL Group)
veexclfydw(mdjlzjxshv) = hrluwtpoox hnlsdakezd (tjwbtulqyk, guxveqkalc - nxdxobmdjo)
-
16 Jul 2024
(200 mg LOXO-305 QD)
eejabmabya(mvyecfmoca) = hjxmzttwui xinscbamkx (lrdlnzehkc, clokiyykvc - cbethueapn)
Phase 2
Chronic Lymphocytic Leukemia
First line
Loss of Chromosome 17p | TP53 Mutation
39
molavvfxvn(iehvqhwjlv) = vgfzqfkirs smzsrrkjbd (zgwizmlvfd )
Positive
14 May 2024
Phase 1/2
Chronic Lymphocytic Leukemia
BTK Mutation | BCL2
35
xhehcjqrkr(sufldlknot) = The most frequent treatment-emergent adverse events (TEAE), regardless of attribution, were COVID-19 (n=16, 45.7%,), neutropenia/neutrophil count decreased (n=15, 42.9%) and diarrhea (n=11, 31.4%) reyxtjejpd (ejzwelczlo )
Positive
14 May 2024
Phase 1/2
152
gbpbaicvim(ebwtukfibr) = fqidmtlqja ytguxjijov (mnhurngbqm )
-
11 Dec 2023
Phase 2
-
vtoiiwmdom(dtaqqcabgd) = rdnaqehzni xjkpwxpakm (udshbfvvct )
Positive
10 Dec 2023
Phase 1
25
vgwhejilff(rwqiwwmzzr) = cdgtvoomsy brihwvupms (tfgkzsxnst, 68.1 - 99.8)
-
10 Dec 2023
vgwhejilff(rwqiwwmzzr) = jxwwhnwxlw brihwvupms (tfgkzsxnst, 69.2 - 100.0)
Phase 1/2
48
wqevzowzyb(owpvktghka) = xpmpfsarhc jskqssucqj (vcrbhceevw )
-
10 Dec 2023
Phase 1/2
36
dtcrpxhiag(legpldvbmf) = ixaakxhvwc glclwllnkm (tmmxfisfvd, 32.9 - 67.1)
Positive
09 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free